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Diabetic Aldehyde Dehydrogenase 2 Mutant
(ALDH2*2) Mice Are More Susceptible to
Cardiac Ischemic-Reperfusion Injury Due
to 4-Hydroxy-2-Nonenal Induced Coronary
Endothelial Cell Damage
Guodong Pan, MD, PhD; Bipradas Roy

, MS; Suresh Selvaraj Palaniyandi

, PhD

BACKGROUND: Aldehyde dehydrogenase-
2 (ALDH2), a mitochondrial enzyme, detoxifies reactive aldehydes such as
4-hydroxy-2-nonenal (4HNE). A highly prevalent E487K mutation in ALDH2 (ALDH2*2) in East Asian people with intrinsic low
ALDH2 activity is implicated in diabetic complications. 4HNE-induced cardiomyocyte dysfunction was studied in diabetic
cardiac damage; however, coronary endothelial cell (CEC) injury in myocardial ischemia-reperfusion injury (IRI) in diabetic mice
has not been studied. Therefore, we hypothesize that the lack of ALDH2 activity exacerbates 4HNE-induced CEC dysfunction
which leads to cardiac damage in ALDH2*2 mutant diabetic mice subjected to myocardial IRI.
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METHODS AND RESULTS: Three weeks after diabetes mellitus (DM) induction, hearts were subjected to IRI either in vivo via left
anterior descending artery occlusion and release or ex vivo IRI by using the Langendorff system. The cardiac performance
was assessed by conscious echocardiography in mice or by inserting a balloon catheter in the left ventricle in the ex vivo
model. Just 3 weeks of DM led to an increase in cardiac 4HNE protein adducts and, cardiac dysfunction, and a decrease in
the number of CECs along with reduced myocardial ALDH2 activity in ALDH2*2 mutant diabetic mice compared with their
wild-type counterparts. Systemic pretreatment with Alda-1 (10 mg/kg per day), an activator of both ALDH2 and ALDH2*2, led
to a reduction in myocardial infarct size and dysfunction, and coronary perfusion pressure upon cardiac IRI by increasing CEC
population and coronary arteriole opening.
CONCLUSIONS: Low ALDH2 activity exacerbates 4HNE-mediated CEC injury and thereby cardiac dysfunction in diabetic mouse
hearts subjected to IRI, which can be reversed by ALDH2 activation.
Key Words: aldehyde dehydrogenase-2 ■ cardiac dysfunction ■ coronary endothelial cells ■ diabetic heart ■ ischemia-reperfusion
injury ■ Langendorff system ■ 4-hydroxy-2-nonenal

4

-
hydroxy-
2-
nonenal (4HNE) is generated upon
lipid peroxidation, which is increased during oxidative stress in the pathological state. 4HNE is
a highly reactive aliphatic aldehyde that can form adducts with cellular macromolecules1,2 and contributes to cytotoxicity.3–9 Increased 4HNE adducts were

found in the diabetic myocardium.10,11 Earlier studies
have pointed out that both ischemia and reperfusion
(IR) contribute to the release of 4HNE.12,13 Accelerated
removal of 4HNE during IR injury (IRI) may protect
the myocardium.14 Aldehyde dehydrogenase (ALDH)
is one of the primary enzyme systems that detoxify

Correspondence to: Suresh Selvaraj Palaniyandi, PhD, FAHA, Division of Hypertension and Vascular Research, Department of Internal Medicine, Henry Ford
Health System, Integrative Biosciences Center (IBio), Room #3402, 6135 Woodward, Detroit, MI 48202.Wayne State University, Detroit, MI. E-mail: spalani2@
hfhs.org
Supplementary Material for this article is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.121.021140
For Sources of Funding and Disclosures, see page 16.
© 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use
is non-commercial and no modifications or adaptations are made.
JAHA is available at: www.ahajournals.org/journal/jaha

J Am Heart Assoc. 2021;10:e021140. DOI: 10.1161/JAHA.121.0211401

Pan et al

ALDH2*2 Sensitizes Diabetic Heart to IRI

CLINICAL PERSPECTIVE
What Is New?

• We demonstrated that 4-hydroxy-2-nonenal exacerbated coronary endothelial cell injury in the
aldehyde dehydrogenase 2 allele diabetic heart
and this damage was further enhanced during
ischemia-reperfusion injury.
• Direct 4-
hydroxy-
2-
nonenal infusion to the
myocardium decreased the number of open
arterioles and increased the number of closed
arterioles demonstrating the possible mechanism of how 4-
hydroxy-
2-
nonenal exerts its
toxic effects in the diabetic myocardium.
• Systemic treatment of aldehyde dehydrogenase
2 activator, Alda-1, for just 1 day was sufficient to
confer cardio protection in diabetic hearts that
are subjected to ischemia-reperfusion injury; this
is the first report that shows the acute effects
of Alda-
1 treatment on preventing ischemia-
reperfusion-induced injury in diabetic hearts.

What Are the Clinical Implications?
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• Treatment with Alda-1 like aldehyde dehydrogenase 2 activators or strategies that mitigate
4-hydroxy-2-nonenal toxicity can be considered
as treatment strategy of patients with diabetes
mellitus (DM) and myocardial ischemic events,
more so for patients with DM and the aldehyde
dehydrogenase 2 allele mutation.

Nonstandard Abbreviations and Acronyms
4HNE
ALDH2
CECs
DM
IR
IRI
WT

4-hydroxy-2-nonenal
aldehyde dehydrogenase-2
coronary endothelial cells
diabetes mellitus
ischemia-reperfusion
ischemia-reperfusion injury
wild type

4HNE.15 Reduced ALDH2 activity has been implicated
in cardiac pathologies including diabetic cardiac damage.16,17 A single-
point mutation (E487K) in ALDH2,
termed as ALDH2*2, leads to low intrinsic ALDH2 activity in ≈30% of East Asian people.18–22 Several epidemiological studies in East Asian people indicate
that ALDH2 is critical during cardiovascular diseases.
Inactive ALDH2 genotype is associated with a higher
incidence of myocardial infarction (MI),23,24 angina,25
and diabetes mellitus (DM)26 and its complications.27,28
The myocardial cell population consists of cardiomyocytes as well as noncardiomyocytes including

coronary endothelial cells (CECs), fibroblasts, smooth
muscle cells, nerve cells, and inflammatory cells.
Among these cell types, earlier studies have focused
on cardiomyocytes, the primary functional cells of
the myocardium in the streptozotocin-induced DM
and myocardial IR-induced heart failure, which implicates low ALDH2 activity mediated 4HNE-induced
cardiac pathogenesis.17 Among the noncardiomyocytes, fibroblasts have also been studied.29 However,
in a variety of diabetic complications, microvascular
angiopathy has been implicated as a culprit of pathogenesis but not in diabetic cardiac damage. Thus,
in this study, we wanted to focus on the CECs in diabetic cardiac damage because CECs are the first
cardiac cells to come in direct contact with blood
as they form the inner lining of the blood vessels.
Because of this direct contact, these cells get exposed to hyperglycemia, hyperinsulinemia, oxidative
stress, and inflammatory mediators that are generated during DM. These abnormal metabolic milieus
generate oxidative stress and inflammation in CECs.
This oxidative stress should enhance 4HNE generation in the CECs in diabetic hearts subjected to IRI.
Because we use ALDH2*2 mice that intrinsically have
low ALDH2 activity, studying 4HNE-induced cellular
damage in CECs in diabetic hearts with IRI will provide new information to understand the pathogenesis
for new treatment strategies. Thus, we hypothesized
that 4HNE exacerbates CEC injury in ALDH2*2 diabetic hearts and this damage is further enhanced
during IRI.
We induced myocardial IRI in the ALDH2*2 mutant diabetic mouse hearts via ex vivo and in vivo approaches to mimic the clinical scenarios where patients
with DM experience myocardial ischemic diseases,
such as MI and angina. Alda-1, an agonist of ALDH2
was shown to protect the myocardium against acute
IRI.14 Most important, Alda-1 can activate ALDH2*230
by widening the catalytic tunnel of mutant ALDH2 by
acting as a chemical chaperone. We treated the diabetic ALDH2*2 mice systemically with Alda-1 (10 mg/
kg per day) acutely for 1 day before subjecting them to
IRI ex vivo, by using the Langendorff perfusion system
for the first time, as opposed to intramyocardial acute
Alda-1 treatments in vivo (5 minutes before coronary
artery occlusion) to induce IR and ex vivo (20 minutes
before global IR), as reported in a previous study.14 We
chose a 1-day treatment because this is the shortest
period that an osmotic minipump is available for sustained systemic delivery. First, we treated ALDH2*2
mice with 3 weeks of short-term DM. We then determined if this 1-day Alda-1 treatment protects the myocardium from IRI if the DM duration is chronic, that is,
3 months. Because the only variable in these 2 protocols is the diabetic duration, we were able to identify
whether activating ALDH2 systemically during DM in
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vivo can protect the heart from IRI. Next, we increased
the Alda-1 treatment period to 2 weeks with a 3-month
diabetic period. At the end of the protocols, we evaluated the beneficial effects of systemic Alda-1 treatment to ALDH2*2 diabetic mouse hearts that were
subjected to IRI. The Alda-1 dose was chosen from
previous studies.29,31 Finally, to understand the direct
role of 4HNE in inducing CEC injury, we perfused the
control ALDH2*2 hearts with 50 μmol/L 4HNE (with or
without Alda-1 pretreatment) using Langendorff perfusion system. We assert that our data provide critical
insights for treatment strategy of patients with DM and
myocardial ischemic events, especially for patients
with the ALDH2*2 mutation.

METHODS
The authors declare that all supporting data are available within the article and its online supplementary files.

ALDH2*2 E487K Knock-In Mutant Mice
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ALDH2*2 E487K knock-
in mutant mice that mimic
E487K mutation in East Asian people were developed by Mochly-Rosen as reported earlier.32 Briefly,
ALDH2*2 knock-
in mutation was introduced as a
single nucleotide substitution (G to C) within exon 12
of the ALDH2 genomic fragment corresponding to
the position of human E487K mutation in mice with
a C57/BL6 background by homologous recombination. This was transferred to embryonic stem cells and
then positive embryonic stem cells were microinjected
into C57/BL6 blastocytes and implanted into pseudo
pregnant females. Thus, E487K knock-in mutant mice
were generated. We obtained the ALDH2*2 mice
from Mochly-Rosen group. The mice were bred and
grown in the animal care facility at Henry Ford Health
System and they were genotyped by Transnetyx Inc.
(Cordova, TN). For this study, we used mice of either
sex as DM affects both men and women. We used
C57/BL6 wild type (WT) mice as controls. The animal
protocols were approved by the Henry Ford Health
System Institutional Animal Care and Use Committee.
It adheres to the guiding principles of care and use
of experimental animals per the National Institutes of
Health guidelines. Henry Ford Hospital operates as an
American Association for Accreditation of Laboratory
Animal Care certified animal facility.

Experimental Protocols
Protocol 1: Determine If Streptozotocin-
Induced Type-1 DM Leads to Cardiac Damage in
ALDH2*2 Mutant Mice
We induced type 1 DM with a single intraperitoneal
injection of streptozotocin at a dose of 150 mg/kg

ALDH2*2 Sensitizes Diabetic Heart to IRI

in WT and ALDH2*2 mice at the age of ≈3 months.
After 3 weeks of hyperglycemia (>250 mg/dL),
we measured their cardiac function using
echocardiography and euthanized the mice to perform biochemical and histopathological analysis.
We explained the methodologies in detail in Data
S1.
Protocol 2: Evaluating Potentiation of High-
Glucose Induced Injury in Cultured Endothelial
Cells Along With ALDH2 Inhibition
We pretreated mouse CEC line with 10 μmol/L disulfiram (DSF+), an inhibitor of ALDH2 or vehicle (DSF−)
for 2 hours, and then subjected them to high-glucose
stress 33 mmol/L D-glucose (HG) or 33 mmol/L D-
mannitol as an osmotic control (Ctrl.) for 24 hours.
Earlier we reported that this dose of DSF inhibited
ALDH2 activity and increased 4HNE adducts in cultured cells.33 We described the methods for the following measurements that we performed on the cells
in Data S1: ALDH2 activity, 4HNE protein adducts,
mitochondrial reactive oxygen species, mitochondrial
membrane potential (ΔΨm), and angiogenesis-
tube
formation assay. We pretreated the CECs with either
Alda-1 (20 μmol/L), an activator of ALDH2, with DSF
alone or HG+DSF.
Protocol 3: Induction of Ex Vivo Myocardial IRI in
ALDH2*2 Mutant Diabetic Mice Hearts
We euthanized ALDH2*2 mutant diabetic mice after 3
to 4 weeks of DM induction and, excised and mounted
the hearts on the cannula of the Langendorff perfusion
apparatus (AD Instruments). Then we subjected them
to 30 minutes ischemia and 120 minutes reperfusion
protocol. After, we conducted an experimental analysis
for injury (details in Data S1).
Protocol 4: Induction of In Vivo Myocardial IRI in
ALDH2*2 Mutant Diabetic Mice
Under anesthesia, a midline cervical incision
was created by using a surgical microscope to
separate the skin, muscle, and tissue covering
the trachea using a surgical microscope. An endotracheal tube was inserted and connected to a
rodent ventilator. Under artificial ventilation (110
per minute, 17–18 cm H 2 O), left-s ided thoracotomy between the athird and the fourth rib was
performed. Left anterior descending coronary
artery (LAD) was identified between the pulmonary artery and the left auricle and the ligation of
the LAD was performed. The mice were placed
on a 37°C heat pad for 60 minutes for ischemia.
Then the ligation was released for 2 hours, that is,
reperfusion.
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Table 1.

ALDH2*2 Sensitizes Diabetic Heart to IRI

Change in Body Weight, Heart Weight, and Blood Glucose Levels

Item

Unit

WT Ctrl. (n=5)

WT DM (n=6)

ALDH2*2 Ctrl. (n=6)

ALDH2*2 DM (n=6)

BW

g

31.92±2.10

23.52±2.24*

32.08±2.05

22.20±1.68*,‡

HW

g

0.14±0.01

0.13±0.01

0.14±0.01

0.14±0.02

HW/BW

%

0.45±0.01

0.54±0.07*

†

0.44±0.02

†

0.59±0.09*,‡

†

HW to tibia length

mg/mm

6.37±0.37

5.58±0.35*

6.35±0.68

6.07±0.66

Blood glucose

mg/dL

168.00±22.00

411.67±107.81*

167.00±31.62†

401.67±105.55*,‡

ALDH2*2 indicates aldehyde dehydrogenase 2 mutant allele; BW, body weight; Ctrl., control; DM, diabetes mellitus; HW, heart weight; HW/BW, heart weight
to body weight ratio; HW/TL, heart weight to tibia length; and WT, wild type.
*P<0.05 vs WT Ctrl.
†
P<0.05 vs WT DM.
‡
P<0.05 vs ALDH2*2 Ctrl.

Protocol 5: Effect of Acute Treatment With
ALDH2 Activator, Alda-1 in ALDH2*2 Mutant
Mice With Short-Term and Long-Term Type-1 DM
We treated ALDH2*2 mutant diabetic mice after
3 weeks of DM induction (short term) and 3 months
of DM induction (long term) with Alda-1 (10 mg/kg per
day) or vehicle (dimethyl sulfoxide) acutely for 1 day
using Alzet minipumps. At the end of the treatment period, we euthanized the mice and subjected the hearts
to ex vivo and in vivo IRI protocol as mentioned previously. Next, we evaluated the extent of cardioprotection against IRI by Alda-1 by measuring infarct size,
cardiac function, and coronary perfusion pressure (details in Data S1).
Downloaded from http://ahajournals.org by on October 25, 2021

Protocol 6: Effect of Chronic Treatment With
ALDH2 Activator, Alda-1 in ALDH2*2 Mutant
Mice With Long-Term Type-1 DM
We treated ALDH2*2 mutant diabetic mice after
3 months of DM induction (chronic) with Alda-1 (10 mg/
kg per day) or vehicle (dimethyl sulfoxide) chronically
for 2 weeks using Alzet mini pumps. At the end of the
treatment period, we euthanized the mice and subjected the hearts to IRI protocol and evaluated the
1 as
extent of cardioprotection against IRI by Alda-
mentioned.
Protocol 7: Effect of Acute Alda-1 Treatment on
Acute 4HNE Challenge Mediated CEC Injury,
Ex Vivo
We challenged the isolated hearts of ALDH2*2 control
mice (nondiabetic) with 4HNE (50 μmol/L or dimethyl

sulfoxide for 30 minutes) in Langendorff apparatus. We
chose 50 μmol/L of 4HNE; as per previous studies,
this dose damaged microvascular endothelial cells34
and CECs.35 In another set of mice, before the 4HNE
challenge, we treated the ALDH2*2 control mice with
Alda-1 acutely for 1 day using Alzet mini pumps. Finally,
we measured coronary perfusion pressure, cardiac
function, and endothelial cell damage, as mentioned
earlier.

Statistical Analysis
Data are presented as mean±SEM. The means
among groups were compared using 1-way ANOVA.
Student t test was used when we compared the cardiac function between 4HNE infusion with or without
Alda-1. At the least, P<0.05 was considered statistically significant.

RESULTS
Type-1 DM Exacerbates Cardiac
Dysfunction and Fibrosis in ALDH2*2 Mice
Compared With Their WT Counterparts
Injection of streptozotocin-induced type 1 DM in both
WT and ALDH2*2 mutant mice as compared with citrate buffer injected WT and ALDH2*2 mutant mice
(Ctrl.) (Table). After 3 weeks of hyperglycemia, we
found increased diastolic and systolic dysfunction in
ALDH2*2 diabetic mice compared with WT diabetic
mice by using conscious echocardiography (Figure 1A
through 1G) and balloon catheter in Langendorff perfusion system (Figure S1). We also observed an increase

Figure 1. ALDH2*2 mutant and wild type (WT) mice with type-1 diabetes mellitus (DM) decreased cardiac function and
increased cardiac fibrosis when compared with ALDH2*2 and WT control mice without DM.
Fractional shortening (FS) % (A), ejection fraction (EF) % (B), heart rate (HR), (C), anterior wall thickness (AWT) (D), posterior wall
thickness (PWT) (E), left ventricular end-diastolic diameter (LVDd) (F), left ventricular end-systolic diameter (LVDs) (G), microscopic
images of cardiac fibrosis (H through K) and its quantification (L), ALDH2 activity (M), Western blots of 4-hydroxy-2-nonenal (4HNE)
adducts (N) and its quantification data (O) were shown from ALDH2*2 mutant diabetic mice and nondiabetic control ALDH2*2 mutant
mice (Ctrl.) and respective WT mice. Data are presented as mean±SEM. *P<0.05, **P<0.01, and ***P<0.001. N=6. ALDH2*2 indicates
aldehyde dehydrogenase 2 mutant allele; Ctrl., control.
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N

O

in cardiac fibrosis in both ALDH2*2 mutant and WT diabetic mice compared with ALDH2*2 mutant and WT
control mice (Figure 1H through 1L). This increase in

cardiac fibrosis was higher in ALDH2*2 diabetic mice
compared with WT diabetic mice (Figure 1H through
1L).
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Type-1 DM Exacerbates the Decrease
in ALDH2 Activity and Increase in 4HNE
Adducts in ALDH2*2 Mice
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Short-term hyperglycemia of type 1 DM (ie, 3 weeks)
significantly decreased myocardial ALDH2 activity in ALDH2*2 mutant mice compared with their
nondiabetic controls (Figure 1M). However, the
ALDH2 activity was slightly decreased in WT diabetic mice compared with their nondiabetic controls (Figure 1M). Furthermore, among the diabetic
groups, the myocardial ALDH2 activity was significantly reduced in ALDH2*2 mutant diabetic mice
compared with their WT counterparts (Figure 1M).
As previously established in the literature, we noted
that myocardial ALDH2 activity was significantly
lower in nondiabetic ALDH2*2 mice (Figure 1M).
On the other hand, type 1 DM significantly increased cardiac tissue 4HNE adduct levels in WT
and ALDH2*2 mice compared with their nondiabetic controls (Figure 1N and 1O); This increase
was higher in ALDH2*2 diabetic mice compared
with WT diabetic mice (Figure 1N and 1O). Again,
even in normal condition, cardiac 4HNE protein
adducts were significantly higher in ALDH2*2 mutant mice compared with WT mice (Figure 1N and
1O). Several proteins showed increased 4HNE
adductions as evident from increased intensity in
the immunoblotting bands in both ALDH2*2 mutant and WT mice with DM compared with their
respective nondiabetic controls (Figure 1N and 1O).
The band intensities were higher in ALDH2*2 diabetic samples compared with WT diabetic samples
(Figure 1N and 1O). The ALDH2 protein levels in
CD31+ CECs were lower in diabetic hearts of both
WT and ALDH2*2 mice compared with their nondiabetic counterparts (Figure S2). Also, it is noteworthy that ALDH2 levels were lower in nondiabetic
ALDH2*2 mutant mice compared with nondiabetic
WT mice (Figure S2). The decrease in ALDH2 levels
in the tissues of ALDH2*2 mutant mice is due to
low stability of ALDH2*2 protein as demonstrated
by Jin et al.36 These results suggest that DM and
ALDH2*2 mutation contribute to the changes
in cardiac ALDH2 activity and 4HNE adducts
level. Furthermore ALDH2*2 mutations augments

ALDH2*2 Sensitizes Diabetic Heart to IRI

DM-m ediated decrease in ALDH2 activity and increase in 4HNE adducts level.

Type 1 DM Exacerbates a Decrease in
the Number and Function of CECs in
ALDH2*2 Mice
We found that type 1 DM decreased the number of
CECs in the myocardium of WT slightly as compared
with nondiabetic WT controls (Figure 2A through 2E).
However, this decrease was significantly exacerbated
in ALDH2*2 diabetic mice (Figure 2A through 2E). We
also found a significant increase in the coronary perfusion pressure in ALDH2*2 diabetic mice compared
with its controls (Figure 2F); Also, coronary perfusion pressure increase was significantly enhanced
in ALDH2*2 diabetic mice compared with WT diabetic mice (Figure 2F). Next, we found a decrease in
endothelial nitric-
oxide synthase (eNOS) in CD31+
CECs in diabetic heart tissue sections as compared
with nondiabetic controls (Figure 2G through 2R) and
this decrease was displayed higher in the hearts of
ALDH2*2 diabetic mice compared with WT diabetic
mice. We also found a decrease in eNOS protein levels (Figure 2S and 2T), eNOS phosphorylation at serine 1177 (Figure 2S and 2U), and the ratio of phospho
eNOS and eNOS (Figure 2V) in the cardiac lysates
of ALDH2*2 mutant diabetic mice as compared with
WT diabetic mice. We inferred from these data that in
diabetic cardiomyopathy, low ALDH2 activity contributes to the CEC loss, decreased coronary function,
and reduced eNOS levels and their phosphorylation
in CECs.

ALDH2 Inhibition Potentiates High
Glucose-Induced CEC Injury
ALDH2 inhibition by DSF+ augmented hHG stress induced decrease in ALDH2 activity (Figure S3A) and
increase in 4HNE adduction (Figure S3B and S3C) in
cultured CECs.
DSF+ augmented HG-
induced decrease in viability of CECs (Figure 3A through 3E) as compared
with cells treated with HG with DSF− and control
cells. Similarly, DSF+ enhanced HG mediated decrease in blood vessel tube formation (angiogenesis),

Figure 2. Decrease in coronary endothelial cell (CEC)s, endothelial nitric oxide (eNOS) and eNOS phosphorylation in type-1
diabetic hearts when compared between ALDH2*2 mutant and WT control mice.
Representative micrographs of CD31+ immunostaining of CECs of cardiac sections (A through D) and the quantification of the number
of CECs in cardiac sections (E) were shown from WT and ALDH2*2 control (Ctrl.) and diabetic mellitus (DM) mice. Quantification data of
myocardial coronary perfusion pressure (F) were shown from WT and ALDH2*2 Ctrl. and DM mice. Data are presented as mean±SEM.
Representative micrographs of double staining of CD31+ and endothelial nitric-oxide synthase (eNOS) immunofluorescence staining in
CECs of cardiac sections were shown from WT and ALDH2*2 Ctrl. and DM (G through R). The quantification data of CD31+ cells (S) and
eNOS + cells (T) were shown. Representative Western blot images of eNOS, phospho eNOS (p-eNOS), and porin levels (U) and eNOS
quantification data (V), phospho eNOS S1177 (W), and the ratio of phospho eNOS S1177/eNOS (X) were shown. Data are presented as
mean±SEM. *P<0.05, **P<0.01, and ***P<0.001. N=6. ALDH2*2 indicates aldehyde dehydrogenase 2 allele; and WT, wild type.

J Am Heart Assoc. 2021;10:e021140. DOI: 10.1161/JAHA.121.0211406

Pan et al

ALDH2*2 Sensitizes Diabetic Heart to IRI

E

G

A

C

B

D

H

F

I
S

Downloaded from http://ahajournals.org by on October 25, 2021

J

K

L

M

N

O
T

P

Q

U

a functional assay of CECs (Figure 3F through 3J).
Pretreatment with DSF+ augmented HG induced
an increase in mitochondrial membrane potential
(Figure 3K through 3O) and mitochondrial reactive

R

V

W

X

oxygen species (Figure 3P) in cultured CECs. We
also found that the 4HNE was significantly colocalized with mitochondria (Figure S4). Once again, the
immunostaining data also showed increased 4HNE
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adducts with HG stress, which was potentiated with
ALDH2 inhibition via DSF+ (Figure S4).
Though HG alone did not decrease eNOS levels
(ratio of dimer and monmer), phospho eNOS S1177
or increase phospho eNOS T495 levels (Figure S5A
through S5E), it reduced the ratio of phospho eNOS
S1177 and phospho eNOS T495 (Figure S5F). These
changes were enhanced by ALDH2 inhibition with
DSF either alone or combined with DSF (Figure S5A
through S5F). Our in vitro studies established that
low ALDH2 activity via DSF mediated ALDH2 inhibition potentiated HG stress-m ediated CEC death
(decreased cell viability), whereas dysfunction (decrease in tube formation and S1177 phospho eNOS
level as well as increase in phospho eNOS T495)
and metabolic abnormality (increased mitochondrial membrane potential and mitochondrial reactive
oxygen species) occurred perhaps via augmented
formation of 4HNE adducts. The results of this hyperglycemic cell culture model were in accordance
with our in vivo data. This reaffirmed our notion
that low ALDH2 activity mediated increase in 4HNE
may form adducts with eNOS and thus decrease
its phosphorylation and levels, and thus it ultimately
enhances CEC damage in diabetic conditions.
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Acute Myocardial IRI Was Exacerbated in
ALDH2*2 Diabetic Mice
Infarct size was increased in the hearts of both
ALDH2*2 diabetic and WT diabetic mice that were
subjected to IRI compared with ALDH2*2 diabetic
and WT diabetic mouse hearts that were just subjected to sham operation. This increase in IRI-induced
infarction was higher in hearts of ALDH2*2 diabetic
mice compared with the hearts of WT diabetic mice
(Figure 4A and 4B). Cardiac functional deterioration
(HR [Figure 4C], LVP [Figure 4D], +dP/dt [Figure 4E]
and −dP/dt [Figure 4F]) was also observed to be significantly higher in ALDH2*2 diabetic mice compared
with WT diabetic mice when measured using the balloon catheter. It is noteworthy to mention that LVP
(Figure 4D) and +dP/dt (Figure 4E) were significantly
decreased in ALDH2*2 diabetic mice compared with
the hearts of WT diabetic mice. Myocardial perfusion pressure was significantly increased in ALDH2*2
diabetic mice compared with their non-
diabetic
controls, and it was also significantly increased in
ALDH2*2 diabetic mice compared with WT diabetic mice (Figure 4G). These IRI studies confirmed
that ALDH2*2 diabetic hearts are prone to IRI compared with WT mice, which indorse the salutary role
of ALDH2 activity in IRI in the diabetic myocardium.
This notion was again reaffirmed as sham-operated
ALDH2*2 mice show significantly jeopardized cardiac
function compared with their WT counterparts.

ALDH2*2 Sensitizes Diabetic Heart to IRI

Acute Myocardial IRI Worsens CEC
Apoptosis in the Myocardium of ALDH2*2
Diabetic Mice
CD31+ CECs were decreased in the myocardium of
sham-operated ALDH2*2 diabetic mice as compared
with sham operated WT diabetic mice (Figure 4H, 4K,
and 4T). This decrease in CD31+ CECs were further
enhanced in the myocardium of ALDH2*2 diabetic
mice after IRI as compared with WT diabetic mice
with IRI (Figure 4Q, 4N, and 4T). There were significant decreases in CD31+ cells in both ALDH2*2 diabetic and WT diabetic mice with IRI compared with
their respective sham-operated controls (Figure 4T).
Apoptotic death of CECs (as evident from increased
TUNEL staining on CD31+ CECs [Figure 4I, 4J, 4L, 4M,
4U, and 4V] as well as increased levels of cleaved caspase 3, an apoptotic index in VEGFR2+ CECs of the
myocardium [Figure S6]) was found in the myocardium
of sham operated ALDH2*2 diabetic mice compared
with sham operated WT diabetic mice. Additionally,
IRI increased the CEC apoptosis in WT diabetic and
ALDH2*2 diabetic mice compared with their sham-
operated counter parts (Figure 4H through 4V and
Figure S6). The salient observation here is that this apoptotic death in CECs of the myocardium was further
enhanced in ALDH2*2 diabetic mice after IRI as compared with WT diabetic mice with IRI (Figure 4R, 4O,
4S, and 4P as well as Figure 4U and 4V and Figure S6).
Our microscopic studies suggest that DM-induced low
ALDH2 activity and ALDH2*2 mutations, which have
low ALDH2 activity makes the diabetic heart more susceptible to IRI-induced CEC apoptosis.

One-Day Alda-1 Treatment Protects
Diabetic Heart With Short-Term
Hyperglycemia From IR-Mediated Injury
in ALDH2*2 Diabetic Mice in Both the Ex
Vivo Langendorff Heart Model and In Vivo
Model
One-day Alda-1 treatment decreased the IRI-mediated
myocardial infarct size in hearts subjected to IRI via
Langendorff apparatus ex vivo (Figure 5A and 5B)
and LAD occlusion in vivo (Figure S7A and S7B) of
ALDH2*2 mice with short-term DM (3 weeks of DM).
One-day Alda-1 treatment improved cardiac function
(Figure 5C through 5F) and decreased the myocardial
perfusion pressure (Figure 5G) in ALDH2*2 mice with
short-term DM. Alda-1 decreased apoptotic death in
CECs (Figure 5H through 5P and 5R) and increased
the CEC density (Figure 5J and 5Q) in ALDH2*2 diabetic mice.
One-day Alda-1 treatment did not protect the hearts
of ALDH2*2 mice with chronic DM from IRI (3 months
of DM) (Figure S8A through S8D), however, chronic
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Figure 3. High glucose decreases cell viability and angiogenesis (tube formation) and increases
mitochondrial membrane potential and oxidative stress (mitosox) in cultured coronary endothelial
cell (CEC) lines.
Representative Hoffman modulation-contrast microscopic images of CECs were shown (A through D).
The data quantification of viable cells was shown (E). Representative micrographs of tube formation of
cultured CECs (F through I) and quantification of tube formation (J). Representative fluorescent images of
JC-1 staining of CECs (K through N) and quantification of the ratio of JC-1 Red and JC-1 Green (O) were
shown. Data quantification of mitosox staining of cultured CECs (P). Data are presented as mean± SEM.
*P<0.05, **P<0.01, and ***P<0.001. N=6. DSF indicates disulfiram; HG, high glucose; and WT, wild type.
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Alda-1 treatment ie for 2 weeks, protected hearts of
ALDH2*2 mice with chronic DM from IRI (Figure S8E
through S8H). Finally, we found that Alda-1 increased
ALDH2 activity (Figure S9A) and decreased 4HNE adduct levels (Figure S9B and S9C) compared with vehicle, which could be the underlying mechanism for the
observed beneficial effects of Alda-1. These treatment
strategies provided the critical information that we can
increase ALDH2 activity in ALDH2*2 diabetic mice,
which intrinsically have low ALDH2 activity that is further reduced by DM. However, the treatment duration
is critical. If the duration of DM is longer, then we need
longer ALDH2 activation. This information is very critical to translate such preclinical studies into clinic.

Alda-1 Protected 4HNE Induced CEC
Injury in the Heart of ALDH2*2 Mice

Downloaded from http://ahajournals.org by on October 25, 2021

From above protocols, we drew a notion that ALDH2
activity is very important in diabetic hearts to attenuate
damage after IR insult for decreasing 4HNE-mediated
tissue damage. Finally, we wanted to determine the direct role for 4HNE in inducing CEC injury in the myocardium. Therefore, we infused a pathological dose of
4HNE (50 µmol/L) which increased cardiac dysfunction
acutely (Figure 6A through 6C) and perfusion pressure
(Figure 6D) in the isolated hearts of control ALDH2*2
mice (having low ALDH2 activity will not allow for metabolism of 4HNE efficiently) compared with the basal
value. Alda-1 pretreatment attenuated 4HNE-induced
cardiac dysfunction (Figure 6A through 6C) and perfusion pressure (Figure 6D) in isolated hearts from
non-diabetic ALDH2*2 mice. 4HNE infusion deceased
number of open arterioles and increased the number
of closed arterioles in the myocardium of ALDH2*2
non-diabetic mice compared with controls (Figure 6E
through 6L). Alda-1 pretreatment increased the number of open arterioles and decreased the number
of closed coronary arterioles after 4HNE infusion in
the hearts of ALDH2*2 non-diabetic mice (Figure 6E
through 6L).
CD31+ CEC density was not changed in the hearts
of ALDH2*2 mice with 4HNE infusion and Alda-1 treatment (Figure 6M, 6P, 6S, and 6V) as they are normal
non-diabetic mice. However, 4HNE infusion decreased
eNOS levels in the hearts of ALDH2*2 control mice

ALDH2*2 Sensitizes Diabetic Heart to IRI

compared with untreated ALDH2*2 control mice while
Alda-
1 pretreatment increased eNOS levels in the
hearts of ALDH2*2 control mice infused with 4HNE
(Figure 6M through 6X). Next, we found 4HNE infusion decreased eNOS+CD31+ CECs in the hearts of
ALDH2*2 control mice compared with untreated controls which was increased by Alda-1 in the hearts of
ALDH2*2 control mice infused with 4HNE (Figure 6M
through 6X). Alda-
1 attenuated DSF and DSF+HG
mediated increases in 4HNE adducts in CECs by preventing ALDH2 impairment as well as it also improved
eNOS signaling as it was evident from increases in
eNOS, phospho eNOS S1177 and decrease in phospho eNOS T495.
This direct and acute infusion of 4HNE implicated
that 4HNE can affect coronary arterioles and CECs directly and can lead to cardiac dysfunction when they
have low ALDH2 activity. This 4HNE-
induced CEC
damage and associated myocardial dysfunction can
be reverted by activating ALDH2*2 with Alda-1.

DISCUSSION
In this study, we found cardiac dysfunction and fibrosis were enhanced significantly in ALDH2*2 mice
compared with age-matched WT mice after 3 weeks
of type 1 DM. We found reduction in the population of
CD31+ CECs in the hearts of ALDH2*2 diabetic mice
compared with WT diabetic mice. Additionally, a significant decrease in phospho eNOS (ser 1177) and eNOS
levels was observed in the myocardium, specifically in
CD31+ CECs in ALDH2*2 diabetic mice as compared
with WT diabetic mice. As a result of decrease in CECs
and eNOS phosphorylation, there was an increase in
coronary perfusion pressure, a measure of poor coronary perfusion, in ALDH2*2 diabetic mice. When we
subjected the ALDH2*2 diabetic hearts to ex vivo and
in vivo IRI, the myocardial infarct size was increased in
ALDH2*2 diabetic mice as compared with WT diabetic
mice. Cardiac dysfunction and coronary perfusion
pressure were enhanced in ALDH2*2 diabetic mice as
compared with WT diabetic mice when subjected to
IRI. We also observed increased apoptosis in CD31+
CECs in the cardiac sections from ALDH2*2 diabetic
mice subjected to IRI. This may be the cause of the

Figure 4. Type 1 DM increases myocardial ischemia-reperfusion injury in ALDH2*2 mutant diabetic mice as compared with
WT control mice.
Representative macroscopic cardiac sections with 2,3,5-triphenyltetrazolium chloride (TTC) staining (A) and its quantification data (B),
cardiac functional parameters heart rate (C), Left ventricular pressure (LVP) (D), rate of rise in left ventricular pressure (+dP/dt) (E) and
rate of decline in left ventricular pressure (–dP/dt) (F), and quantification data of perfusion pressure (G) were shown in WT and ALDH2*2
diabetic mice with sham operation (Sham) or ischemia-reperfusion injury (IRI). Representative micrographs of double staining of CD31
and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) immunofluorescence staining in CECs of cardiac sections
(H through S) and the quantification data of staining of CD31 (T), TUNEL (U) and double positive of CD31 and TUNEL (V) were shown
in WT and ALDH2*2 diabetic mice with sham operation (Sham) or ischemia reperfusion injury (IRI). Data are presented as mean±SEM.
*P<0.05, **P<0.01, and ***P<0.001. N=6. ALDH2*2 indicates aldehyde dehydrogenase 2 mutant allele; DM, diabetes mellitus; and WT,
wild type.
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loss of CD31+ CECs in the myocardium of ALDH2*2
diabetic mice subjected to IRI.
Since the myocardium of ALDH2*2 diabetic mice
was damaged when subjected to IRI, we planned

S

to treat the ALDH2*2 diabetic mice with Alda-1 to
increase the activity of ALDH2*2. Next, systemic
Alda-
1 treatment for just 1-
day conferred cardio
protection. This was done by increasing myocardial
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ALDH2 activity against global IRI (Langendorff ex
vivo model) and local IRI (in vivo model via LAD occlusion) in the ALDH2*2 diabetic mouse heart with
3 weeks of DM.
Alda-1 reduced % infarct size and improved cardiac
function by decreasing DM-mediated 4HNE induced
CEC injury, which is evident from both reduced coronary perfusion pressure and cell death of CD31+
CECs in ALDH2*2 diabetic mice subjected to IRI. To
further directly elucidate the mechanism, we directly
infused 4HNE to the isolated hearts of normal control ALDH2*2 mice. As these mice have low ALDH2
activity this procedure satisfies the purpose perfectly.
Exogenous 4HNE increased the number of arteriole
closure and decreased the number of open arterioles
compared with vehicle. Most important, this direct
4HNE infusion increased coronary perfusion pressure,
implicating coronary endothelial cell dysfunction and
ultimately resulted in cardiac dysfunction. To determine the ameliorative effect of Alda-1 on direct 4HNE
infusion-
mediated deleterious effects, we pretreated
the ALDH2*2 mutant mice systemically with Alda-1 for
just 1 day. This Alda-1 pretreatment protected coronary arterioles from closure and increased both the
number of open arterioles and eNOS+ CD31+ CECs,
and thereby improved cardiac function. To encapsulate, either with DM alone or subject the diabetic hearts
to IRI, we found 4HNE mediated CEC injury was reduced by ALDH2 activation.
Acute MI-induced deaths in patients with DM are 2
times higher than patients without DM.37 The post-MI
prognosis is worse in patients with DM than in patients
without.38,39 There are multiple mechanisms proposed
for acute myocardial IRI.40 4HNE-
induced toxicity is
one such mechanism. 4HNE protein adducts started
to form in the heart at around 10 minutes into ischemia and subsequently peaked around 30 minutes.12
Reperfusion of ischemic cardiac tissue increases
4HNE, which inactivates proteins by forming adducts
on them and ultimately inhibiting mitochondrial respiration.13 Along with this, mitochondrial metabolism of
4HNE and its extrusion from the heart are inhibited in
myocardial ischemia,41 suggesting enhanced accumulation of 4HNE in ischemic conditions. Thus, our
study confirms the present concept of 4HNE-mediated
pathophysiology in IRI. Additionally, it provides a new
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mechanism ie 4HNE mediated CEC dysfunction in
clinically relevant IRI models.
Langendorff ex vivo model of IRI mimics the situation of global IRI which occurs in patients having cardiac arrest and cardiopulmonary resuscitation. There
are more than 350 000 cardiac arrests annually in the
United States.42 Employing Langendorff ex vivo model
of IRI has such clinical relevance besides providing
an experimental system devoid of systemic influence
and studying the cardiac-centric effects. Our results
from this model are equally important as that of the in
vivo IRI model of LAD occlusion. In vivo IRI model via
LAD occlusion creates acute MI in a focal area which
mimics common clinal MI. Roughly 600, 000 acute MI
cases are reported each year in the United States.42
Our study found that Alda-1 had the protective effects
against IRI in both Langendorff heart and acute MI
model, which suggests the potential value of Alda-1
in clinic.
Diabetes mellitus leads to microvascular complications including retinopathy, nephropathy, neuropathy, stroke, atherosclerosis, and cardiomyopathy.
Increased oxidative stress by DM impairs endothelial
cell function and is thought to mediate microvascular
angiopathy. Endothelial function is usually conducted
via eNOS mediated nitric oxide (NO) production and/
or its bioavailability.43 Hyperglycemia and DM lead to
an impairment of eNOS activity and impaired NO production and its activity, thus resulting in endothelial
cell damage, dysfunction and death.44 ALDH2*2 contributes to the decrease in the efficacy of sublingual
nitroglycerin which implied the role of ALDH2 in NO
biotransformation.45 We also found reduced phosphorylation of Serine 1177 in eNOS in low ALDH2
activity with hyperglycemic stress in vivo and in vitro
where 4HNE adduct levels were higher. Thus, we presume 4HNE adduction on eNOS may have prevented
its phosphorylation.
In this study, we found that ALDH2*2 mutation
exacerbated DM-
induced endothelial cell damage
before IRI. Since healthy functional CECs plays a
critical role in minimizing myocardial IRI, the increase
in the impairment of CECs in ALDH2*2 diabetic mice
might have aggravated the outcome of IRI in them.
Our in vitro protocol using mouse CECs revealed that
high-glucose stress mediated mitochondrial stress,

Figure 5. Alda-1, an ALDH2 activator protects against ischemia-reperfusion injury in ALDH2*2 diabetic mice.
Representative macroscopic cardiac sections with 2,3,5-triphenyltetrazolium chloride (TTC) staining (A) and its quantification data (B),
cardiac functional parameters heart rate (C), left ventricular pressure (LVP) (D), rate of rise in left ventricular pressure (+dP/dt) (E) and
rate of decline in left ventricular pressure (–dP/dt) (F), and quantification data of perfusion pressure (G) were shown in ALDH2*2 diabetic
mice with 1-day Vehicle (Vehicle) or Alda-1 (Alda-1) pretreatment, and hereafter sham operation (Sham) or ischemia reperfusion injury
(IRI). Representative micrographs of double staining of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and
CD31 immunofluorescence staining and the merging of both staining in CECs of cardiac sections (H through P) and the quantification
data of staining of CD31 (Q) and TUNEL (R) in ALDH2*2 diabetic mice with Sham, or pretreated with Vehicle or Alda-1 before IRI. Data
are presented as mean±SEM. *P<0.05, **P<0.01, and ***P<0.001. N=6. ALDH2 indicates aldehyde dehydrogenase 2; ALDH2*2, ALDH2
mutant allele; CEC, coronary endothelial cell; and WT, wild type.
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decreased eNOS function, worsened angiogenesis,
and increased death, which were further augmented
by ALDH2 inhibition via DSF treatment. These results
implicate that ALDH2 mediated 4HNE detoxification

P

is important for maintaining healthy and functional
CECs. We also found mitochondrial 4HNE presence
was increased with DSF during high-glucose stress.
Thus, we supposed that the 4HNE-mediated CEC
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injury is critical in diabetic myocardium and loss of
ALDH2 activity exacerbates it. This is evident from
our ALDH2*2 mutant mice carrying low ALDH2 activity having higher CEC apoptosis in normal and
diabetic conditions. In our recent cell culture studies using mouse CECs, we found 4HNE can directly
contribute to decreased CEC cell migration46 and angiogenesis35 which were again exacerbated by DSF
pretreatment.
In earlier studies, the deleterious effects of reduced ALDH2 activity and increased 4HNE adduct
formation in myocardial ischemia or IRI has been
demonstrated.14,47 In a landmark study, Chen et al
showed the correlation between decrease in infarct
size and pharmacological agents that possibly activate ALDH2.14 For the first time, they demonstrated
that ALDH activation by Alda-1 protected the heart
from IRI in the ex vivo and in vivo models of MI.14 In
both models, it was shown that Alda-1 was infused
directly to the myocardium. Levi and colleagues
have demonstrated that degranulation of cardiac
mast cells by 4HNE induced ventricular arrhythmias during acute IR.48 Further they described that
perfusing Alda-
1 directly to the heart attenuated
reperfusion-i nduced arrhythmias.48 In our study,
strikingly systemic treatment of Alda-1 just for 1-d ay
is sufficient to confer cardio protection in diabetic
hearts that are subjected to IRI, which implies potential clinical applicability of Alda-1. This is the first
report which shows the effects of Alda-1 treatment
on preventing IR-induced injury in diabetic hearts.
The IRI in diabetic heart tissue was controversial.49
We observed increased infarct size and poor cardiac function after IRI in diabetic hearts regardless
of their genotypes, but compared with WT mice,
ALDH2*2 mice exhibited more severe myocardial
IRI.
We induced type-1 DM in ALDH2*2 mutant mice
which mimic East Asians with ALDH2*2 mutation anticipating that DM should further decrease ALDH2
activity in ALDH2*2 mice which were already having intrinsically low ALDH2 activity. In humans, patients with
DM and the ALDH2*2 mutation had increased diastolic
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dysfunction compared with patients without DM and
the mutation.28 Our results showing protective effects
with Alda-1 treatment in ALDH2*2 diabetic hearts emphasize the potential of Alda-1 as a therapeutic agent
in diabetic ALDH2*2 carriers.
We found that 4HNE protein adducts levels in the
cardiac homogenates were attenuated by Alda-
1
treatment in ALDH2*2 diabetic mice which implies that
increased ALDH2 activity by Alda-1 led to increased
detoxification of 4HNE. This in turn decreased deleterious effects of 4HNE in CECs ie forming adducts
with critical proteins like eNOS, ultimately conferred
cardio protection. It is well known that increased
4HNE adduct formation in the diabetic heart was
reported in multiple models of DM such as db/db
mice,50 streptozotocin-
induced type-
1 DM in rats16
17,51
and mice,
high-fat diet and low-dose streptozotocin induced type-2 DM,10 and insulin resistance models.52 It was reported that increased 4HNE adduct
formation with the mitochondrial respiratory complex
2 protein, succinyl dehydrogenase was reported in the
streptozotocin-induced type-1 diabetic heart tissue.53
Using the same model, we also found that mitochondrial respiratory complex protein V subunit levels were
decreased in diabetic heart.11 However, in the current
study, we investigated the mechanism of 4HNE induced CEC injury. We found for the first time that the
direct infusion of 4HNE to the isolated hearts causes
closure of coronary arterioles along with a decrease in
eNOS levels in CECs, which might have led to the increased coronary perfusion pressure and myocardial
dysfunction. When we pretreated ALDH2*2 mice with
Alda-1 before the 4HNE challenge, we found that it reduced closure of coronary arterioles and increased the
number of open arterioles. Thus, Alda-1 improved the
coronary perfusion and cardiac function. We postulate that acute 4HNE infusion reduced eNOS levels by
forming adducts with eNOS and then removing 4HNE
adducted eNOS. The duration of acute 4HNE infusion
is short time to reduce the CD31+ cells from the heart.
However, this ex vivo 4HNE study suggested that perhaps decreasing eNOS due to 4HNE adduction eventually decreased the CD31+ endothelial cell density

Figure 6. Pretreatment of mice with systemically delivered Alda-1 protects coronary endothelial cell (CEC)s from 4-hydroxy-
2-nonenal (4HNE) induced damage in control ALDH2*2 mice.
The quantification data of left ventricular pressure (LVP) (A), rate of rise in left ventricular pressure (+dP/dt) (B) rate of decline in left
ventricular pressure (–dP/dt) (C) and perfusion pressure (D) were shown from 4HNE-perfused hearts of nondiabetic ALDH2*2 mice with
vehicle (Vehicle) or Alda-1 pretreatment (Alda-1). Representative micrographs of hematoxylin-eosin (H-E ) stained cardiac sections were
shown from 4HNE-perfused hearts of nondiabetic ALDH2*2 mice with control (Ctrl or no 4HNE perfusion) (E), 4HNE perfusion (4HNE)
(F) and Alda-1 pretreatment before 4HNE perfusion (Alda-1 & 4HNE) (G). The magnifications of the inset boxes were shown in (H through
J) micrographs were in the interstitial region of the midventricle section. The cartoons of open and closed arterioles were shown. The
quantification of data of open (K) and closed (L) coronary arterioles were shown from the interstitial region of the midventricle section.
Representative micrographs of double staining of CD31+ and endothelial nitric-oxide synthase (eNOS) immunofluorescence staining
in CECs of cardiac sections were shown from Ctrl. (M through O), 4HNE (P through R) and Alda-1 & 4HNE groups (S through U). The
quantification of data of CD31 positive (V), eNOS positive (W) and the percentage eNOS positive in CD31 positive CECs (X). Data are
presented as mean±SEM. *P<0.05, **P<0.01, and ***P<0.001. N=6. ALDH2*2 indicates aldehyde dehydrogenase 2 mutant allele.
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in hyperglycemic hearts. Our acute 4HNE infusion
studies pointed out that all these acute changes by
4HNE led to microvascular endothelial cell damage
in hyperglycemic mouse studies. Furthermore, the

U

pretreatment with Alda-1 reversed those deleterious
effects of acute 4HNE infusion suggesting that perhaps Alda-1 prevented IR-induced cardiac injury and
cardiac dysfunction in type-1 DM by protecting the
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CECs and coronary arterioles from DM/IRI induced
4HNE mediated toxicity.

Limitation of the Study
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Even though we provided a significant amount of evidence for ALDH2 activation by Alda-1 mediating beneficial effects through decreasing 4HNE-
mediated
deleterious effects, there are multiple other reactive
aldehydes such as malondialdehyde (MDA)54 and
acrolein55 that also can contribute to myocardial injuries. In fact, we found MDA and acrolein protein
adducts were increased in the hearts of ALDH2*2
mice with DM compared with controls which were
slightly attenuated by Alda-1 treatment (Figures S10
and S11). Nonetheless, these data also underscore
that ALDH2 activity should be important in alleviating tissue damage by decreasing the deleterious effects of reactive aldehydes. Next, it is imperative that
4HNE toxicity as well as ALDH2 activity are critical
in all cardiac cell types, not only CECs. However, we
focused on CEC dysfunction in this study because
there is limited information on ALDH2/4HNE roles
in CECs in diabetic cardiac damage. Moreover, our
intention was not to implicate CEC injury alone as
a cellular mechanism by which IRI injury occurs in
the diabetic myocardium, however the importance of
CEC damage in this pathogenesis. Because, CECs
are the first cardiac cells to encounter diabetic milieu
from the systemic circulation, and that pathogenesis
starts with CECs and the sequence of events follows
to the entire myocardial tissue ie oxidative stress-
inflammation-
cardiac fibrosis-
stiffness and finally
cardiac dysfunction. This is further exacerbated by
IRI-mediated pathological stimuli. We presume CEC
injury is the gatekeeper of the myocardial damage
in DM as well as IRI. Further studies are required
to dissect how CEC injury contributes to the following pathogenic events in diabetic heart damage with
IRI through 4HNE. Finally, identification of 4HNE adducted proteins from both in vitro and in vivo studies
should provide potential cell signaling pathways that
contribute to the pathophysiology of diabetic cardiac
damage in IRI. We propose this could be our future
direction.

CONCLUSIONS
Finally, we want to conclude that acute systemic treatment with Alda-1 even just for 1 day is sufficient to
protect the myocardium from IRI in ALDH2*2 diabetic
mice perhaps via protecting the CECs from 4HNE-
mediated damage. Our data provides initial evidence
to develop pharmacological activators of ALDH2 as
a therapeutic option for IR-induced myocardial injury
in DM.
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Data S1. Supplemental Methods.
Experimental Procedure
Induction of type-1 diabetes by streptozotocin:
Type-1 diabetes was induced in ~3 months of either gender of wild type (WT) C57BL/6
and ALDH2*2 E487K knock-in mutant mice by administering a single intraperitoneal (i.p.)
injection of streptozotocin (STZ) (150 mg/kg). It was prepared freshly in citrate buffer (pH
4.5) for maximal stability. The control group was injected with the vehicle (citrate buffer)
only. To ensure that the animals were diabetic, after 48 hours of STZ injection, mice were
fasted for 6 hours and their blood sample was collected from their tail veins and their
glucose levels were measured with a glucometer. Mice with blood glucose values of >250
mg/dL 48 hrs after STZ injection were considered as diabetic and included in the study.
Blood was collected from the tail vein and glucose was then measured with a glucometer.
The heart weights, body weights and tibial length were also measured and recorded. The
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animal protocol has been approved by the Henry Ford Health System Institutional Animal
Care and Use Committee. It adheres to the guiding principles of the care and use of
experimental animals in accordance with the NIH guidelines. Henry Ford Hospital
operates on an AAALAC certified animal facility with licensed veterinarian and welltrained veterinary technicians. The mice were housed in our animal facility and provided
with normal chow and 24-hour water access. On the day of STZ injection, the mice were
provided with sucrose water to avoid hypoglycemia. Since diabetic animals urinate
enormously, the bedding was changed frequently than control mice. The mice were
housed in a separate and designated-restricted room immediately after STZ until they
excrete urine completely and later moved to normal rooms.

Cardiac functional assessment by echocardiography
After 3 weeks of diabetes induction, the left ventricular dimension and function were
assessed in mice by conscious echocardiography equipped with a 15-MHz linear
transducer (Acuson c256), as described previously10.

Histopathology
The middle portions of the cardiac tissue were fixed with 10% formalin in PBS, embedded
in paraffin as blocks, and several transverse sections were cut for histopathological
studies.

Downloaded from http://ahajournals.org by on October 25, 2021

Measurement of cardiac fibrosis
The myocardial sections were stained with Picrosirius Red. The red color indicates the
deposition of collagen and this area was measured using the MicroSuite software
(Olympus America). The percent (%) area of fibrosis was quantified from each tissue
section as previously described56-58.

Immunohistochemical staining
Formalin-fixed,

paraffin-embedded

cardiac

tissue

sections

were

used

for

immunohistochemical staining. After deparaffinization and hydration, the slides were
washed in Tris-buffered saline (TBS; 10 mmol/L Tris–HCl, 0.85% NaCl, pH 7.5)

containing 0.1% bovine serum albumin (BSA). Endogenous peroxidase activity was
quenched by incubating the slides in 0.6% H2O2/methanol. A pressure cooker method
was used to retrieve the antigen. In the following steps, reagents from an
immunoperoxidase staining kit (Millipore) were used as directed. A solution from the kit
was used to block non-specific reactions. After overnight incubation with polyclonal rabbit
CD-31 antibody at a concentration of 1:100 and 4 °C, the slides were washed in TBS.
Secondary antibody solution and streptavidin peroxidase solution were added and
incubated at room temperature. Immunostaining was visualized with chromogen,
diaminobenzidine tetrahydrochloride (DAB). Finally, the sections were counterstained
with hematoxylin. The CD31+ coronary endothelial cells in the cardiac sections were
counted using light microscope (Olympus) and plotted as a graph.
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Western immunoblotting
Western blot was performed as described earlier

10, 11, 59, 60.

In brief, cardiac protein

samples were separated on SDS-polyacrylamide gels by electrophoresis and the proteins
transferred to immobilon-P membranes (Millipore Sigma). Levels of each proteins in heart
samples that we studied were determined using specific antibodies: anti-4HNECys/His/Lys rabbit polyclonal antibody (Millipore Sigma, 303207), anti-eNOS rabbit
polyclonal antibody (Thermofisher Inc, PA3-031A), anti-serine 1177 phospho eNOS (Cell
Signaling Technology, 9571s), anti-threonine 495 phospho eNOS (Cell Signaling
Technology, 9574S), anti-malondialdehyde (MDA) (Alpha Diagnostic international,
MDA11-S), anti-acrolein antibody (Novus Biological, NBP2-59359), anti-GAPDH
polyclonal antibody (Santa Cruz Biotechnology, sc-365062), anti-aconitase antibody

(Abcam, ab14734), anti-β actin mouse monoclonal antibody (Abcam, sc-47778) and antiporin mouse monoclonal antibody (Abcam, 459500). All the antibodies are used at a
concentration of 1:1000. The bound antibody was visualized with horseradish peroxidase
(HRP)-coupled secondary antibody. The band intensifies were quantified using Image J
software.

ALDH activity assay
ALDH2 activity was measured as described elsewhere [10, 11]. In brief, enzymatic activity
of ALDH2 from cardiac tissue homogenates and cell lysates from MCECs were
determined spectrophotometrically by reductive reaction of NAD+ to NADH at λ340 nm.
All assays were carried out at 25ºC in 0.1M sodium pyrophosphate buffer, pH = 9.5 with
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2.4 mM NAD+ as a cofactor and 10 mM acetaldehyde as the substrate.

Immunofluorescence staining
Formalin-fixed and paraffin-embedded cardiac tissue sections were used for
immunostaining. After deparaffinization and hydration, the slides were washed in Trisbuffered saline (TBS; 10 mmol/L Tris–HCl, 0.85% NaCl, pH 7.5) containing 0.1% bovine
serum albumin (BSA). A pressure cooker method was used to retrieve the antigen. In the
following steps, reagents from an immunoperoxidase staining kit (Millipore) were used as
directed. A solution from the kit was used to block non-specific reactions. The following
antibodies were used for co-immunostaining at a concentration of 1:100 and 4 °C for

overnight incubation: anti-CD-31 mouse monoclonal antibody (Abcam, ab24590), antieNOS rabbit polyclonal antibody (Thermofisher Scientific Inc, PA3-031A), anti-4HNECys/His/Lys rabbit polyclonal antibody (Millipore Sigma, 303207), anti-cleaved caspase
mouse monoclonal antibody (Cell Signaling Technology Inc, sc-7148) and anti-VEGFR2
rabbit antibody (Cell Signaling Technology Inc, 55B11). Similarly, the MCECs were
stained after the treatment protocols for co-localizing 4HNE-protein adducts (Millipore
Sigma, 303207) and anti-aconitase mouse antibody (Abcam, ab14734). The secondary
antibodies conjugated with FITC and rhodamine (Thermofischer Scientific Inc) at a
concentration of 1:500 at room temperature for 1 hour. Immunofluorescence positive
staining was analyzed using Olympus microscope and image analyzer.
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Culturing of microvascular coronary endothelial cells
Microvascular coronary endothelial cell (MCEC) line (Cedarlane Labs) was grown in 100
mm plates containing Dulbecco's Modified Eagle Medium (DMEM) (GE Life sciences)
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S).
The cells were incubated at 37ºC with a continuous supply of 5% CO2 in a CO2 incubator.
Once the MCECs became ~50% confluent at fourth passage, the cells were washed two
times with phosphate buffer saline (PBS) followed by addition of new DMEM with 0.2%
FBS (low serum) and 1% P/S. Cell viability assay and collection of cell lysates for protein
extraction were also done in the same time frame.

Trypan blue exclusion cell death assay in microvascular coronary endothelial cells

MCECs grown at 60-70% confluence were starved for 1 hr using DMEM media without
serum. The plates were then divided into the following treatment groups (n=6 plates
each). At the end of the protocol, cells were washed with TBS buffer and trypsinized.
Trypan blue was added at a concentration of 1:1 and subsequently cells were counted
using manual neubauer counting chamber to determine the % of live cells remaining.

Mitochondrial membrane potential
After subjecting to designated treatments, the MCECs were stained with JC-1, the
cationic dye which exhibits potential-dependent accumulation in mitochondria. Under the
excitation at 488 nm, JC-1 exist as a monomer with a green fluorescence at low
membrane potentials (emission at 529 nm) whereas at high membrane potentials JC-1
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forms J aggregates with red fluorescence (emission at 590 nm). The ratio of red vs green
fluorescence was quantified to determine the membrane potential.

Mitochondrial ROS measurement
MitoSOX reagent was used to measure mitochondrial ROS as explained in the
manufacturer’s instructions. 1.0–2.0 mL of 5 μM MitoSOX reagent working solution was
used to cover MCECs and incubated for 10 minutes at 37°C, protected from light. After
washing cells with warm buffer, cells were quantified for the fluorescence using Synergy
H1 Multi-Mode Reader (BioTek Inc). Red fluorescence (Absorption/emission wavelength:

510/580 nm) was dynamically measured for 30 minutes. The delta of fluorescent intensity
reflected the produce of mtROS for 30 minutes.

Tube formation Assay
Preparation of matrigel: Growth factor reduced matrigel (Corning) was thawed overnight
in ice in cold room (40C). A box of sterilized 1 ml pipette tips and a sterilized 24 well plate
were kept in the cold room. Next day 250 µl of liquid matrigel were transferred very
carefully (to avoid bubble formation) in each well of the 24 well plate (required number of
wells were decided by our experimental design.) using the 1 ml cold pipette tips in cold
room. Once the transfer was done, the plate with the gel was immediately incubated for
30 minutes at 370C in order for the gel to solidify. Tube formation: 105 cells were diluted
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in 100 µl DMEM supplemented with 10% FBS and 1% P/S, and subsequently applied to
individual Matrigel-containing wells.

Cells were treated according to the treatment

protocol in figure 1. Microscopy and quantification: Images of tube formation on
matrigel were captured with a phase contrast microscope (Olympus IX81) at 10X
magnification. 12 images were taken from each of the treatment groups. The numbers of
tube formation of blood vessel were counted manually (unbiased) with ImageJ software.
This quantification was compiled on excel spreadsheets for further statistical analysis.

Ex vivo ischemia and reperfusion protocol by Langendorff perfusion technique

The mice were sacrificed, and the hearts were mounted on the cannula of the Langendorff
perfusion apparatus (AD Instruments). The hearts were perfused with Krebs Henseleit
(K-H) buffer equilibrated with a gas mixture comprised of 95% O2 and 5% CO2 pt. After
initial 20 min of stabilization period, the hearts were subjected to 30 min. global ischemia
and 90 min. reperfusion using Langendorff perfusion system. The global ischemia was
induced by stopping the perfusion of K-H buffer and restoration of K-H buffer perfusion is
regarded as reperfusion. Cardiac performance was assessed by inserting a small latex
balloon catheter in the left ventricle. The cardiac contraction sensed by the latex balloon
catheter was transmitted to Power lab system using a transducer. Heart rate, left
ventricular pressure (LVP), left ventricular pressure rise (+dP/dt) and decline (–dP/dt),
and coronary perfusion pressure were recorded, analyzed and calculated using lab chart
software (Adinstruments, Lab Chart 7.3.8 Windows).
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In vivo ischemia and reperfusion protocol by left anterior descending coronary
artery (LAD) ligation and release
Briefly, mice were anesthetized with Inactin (100 mg/Kg) and placed on its back. Under
microscopic view perform a midline cervical incision separating the skin, muscle and
tissue covering the trachea. An endotracheal tube was inserted and connected to a rodent
ventilator. Under artificial ventilation (110 per minute, 17-18 cm H2O), left-sided
thoracotomy between the 3rd and the 4th rib was performed. The LAD is located between
the pulmonary artery and the left auricle. Use an 8-0 suture to ligate the LAD proximal
with one single suture. The mice were placed on a 37 ºC heat pad for 60 minutes for
ischemia. Then the ligation was released which was the reperfusion phase. Mice were

sacrificed after 2 hours reperfusion and hearts were isolated. The infarction areas were
evaluated by TTC staining.

Infarct size measurement by triphenyl tetrazolium chloride (TTC) staining
After the end of IR protocol, the heart was cut into 2‐mm transverse slices in the midcardiac tissue. The slices were incubated in 1% TTC (pH 7.4) at 37°C for 5 min and then
placed in 4% formaldehyde for quantitative analysis. The unstained infarcted heart
showed pale white in color viable heart tissue showed red in color. After scanning the
slices, the percentage of infarcted versus non-infarcted regions were analyzed using the
ImageJ software and expressed as the percentage of cardiac tissue with infarction versus
total area.
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TUNEL apoptosis in cardiac sections
As mentioned earlier procedure the cardiac sections were deparaffinized and then the
cells were stained with In Situ Cell Death Detection kit (Sigma) to detect TUNEL + cells
as per manufacturer’s instructions. The microscopic images were captured and TUNEL+
cells were counted and quantified.

Quantification of open and closed arterioles in the cardiac sections
All the hearts were subjected to perfusion fixation protocol (4% paraformaldehyde) as per
standard procedure 61 and then processed for paraffin cutting and staining protocol. Using

bright field micrographs of the hematoxylin-eosin stained mouse cardiac sections, the
number of open and closed arterioles were analyzed and quantified.
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Supplemental Figure Legends:

Figure S1. Effects of type-1 diabetes mellitus (DM) on cardiac function measured
using balloon catheter in Langendorff apparatus at the basal. The cardiac
functional parameters, LVP (A), +dP/dt (B), heart rate (C) and -dP/dt (D) were shown in
DM and control (Ctrl) in wild type (WT) and ALDH2*2 mutant mice. Data are presented
as mean ± SEM. *p<0.05; **p<0.01

Figure S2. Decrease in ALDH2 levels in CD31+ coronary endothelial cells in the
hearts of WT and ALDH2*2 mutant mice with type-1 diabetes mellitus (DM)
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compared

to

non-diabetic

controls.

Representative

micrographs

of

immunostaining with CD31 (A, D, G, and J), ALDH2 (B, E, H and K) and their merging
(C, F, I and L) in cardiac sections were shown. The quantification of double
immunopositivity (M). Data are presented as mean ± SEM. ***p<0.001

Figure S3. Effects of high glucose (HG) stress with or without disulfiram
(DSF) or Alda-1 pretreatment on 4HNE adducts and ALDH2 activity. ALDH2
activity data (A), Western blot images of 4HNE protein adducts (B) and the
densitometric quantification data of individual bands (C) were measured in cultured
coronary endothelial cells which were subjected to normal glucose (NG) and high glucose

(HG) stress with or without disulfiram (DSF) and Alda-1 pretreatments. Data are
presented as mean ± standard error of the mean (SEM).
*p<0.05, **p<0.01 ***p<0.001

Figure S4. Changes in 4HNE protein adducts in mitochondria in mouse coronary
endothelial cell lines after high glucose (HG) stress and disulfiram (DSF)
treatment.

Representative

immunofluorescence

micrographs

of

showing

co-

immunostaining of 4HNE and aconitase in mouse coronary endothelial cell lines. In
control cells without DSF (Ctrl. DSF-), 4HNE adducts were lower (A and C) and slightly
higher levels of 4HNE were found with DSF (Ctrl. DSF+) (G and I). In high-glucose
stress (HG DSF-), there was increased 4HNE adduct levels in the mitochondria (D and
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F) and which was further increased with DSF treatment (HG DSF+) (J and L).
Micrographs B, E, H and K show aconitase was used as a mitochondrial marker.

Figure S5. Levels of eNOS and its phosphorylation in mouse coronary endothelial
cell lines after high glucose (HG) stress and, disulfiram (DSF) and Alda-1
treatments. Representative Western blot images of eNOS monomer and dimer bands
and β-actin bands (A), and their band density quantification data (B). Representative
Western blot images of p-eNOS serine1177, p-eNOS Threonine 495, eNOS and β-actin
bands (C) from mouse coronary endothelial cell lines that were subjected to the
treatments of normal glucose (NG), HG stress, disulfiram and Alda-1. The ratios of
densitometric quantification of phospho eNOS Serine 1177/eNOS (D), phospho eNOS

Thr 495/eNOS (E) and phospho eNOS Serine 1177/ phospho eNOS Thr 495 were shown
(F). Data are presented as mean ± SEM. N=4-6

Figure S6. Increased apoptosis of coronary endothelial cells of diabetic
myocardium after ischemia reperfusion injury (IRI) in WT and ALDH2*2 mutant
mice. Representative micrographs of double staining of VEGF R2 (A, D, G and J) and
cleaved caspase-3 (B, E, H and K) immunofluorescence staining in coronary
endothelial cells of cardiac sections were shown from WT (A-F) and ALDH2*2 (G-L)
diabetic mice with sham operation (Sham) (A-C and G-I) or IRI (D-F and J-L). N=4-6
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Figure S7. One-day Alda-1 pretreatment protects against ischemia-reperfusion
injury by occluding and releasing left anterior descending (LAD) artery in
ALDH2*2 diabetic mice. Representative macroscopic cardiac sections with TTC
staining (A) and its quantification data (B) were shown in ALDH2*2 diabetic mice with 60
minutes LAD-ligation and subsequent 120 minutes reperfusion. Data are presented as
mean ± SEM. **p<0.01, ***p<0.001 N=4

Figure S8. Effects of one-day Alda-1 pretreatment in ALDH2*2 mice with 3
months type-1 diabetes on cardiac function. One-day Alda-1 pretreatment in
ALDH2*2 mice with 3 months of type-1 diabetes did not improve cardiac function as

shown in LVP (A), +dP/dt (B), -dP/dt (C) and as well as myocardial coronary perfusion
pressure (D) after ischemia-reperfusion injury (IRI) compared to Sham-operated controls.
Data are presented as mean ± SEM.

Effect of two-weeks of Alda-1 pretreatment in ALDH2*2 mice with 3 months type-1
diabetes on cardiac function. Two-weeks of Alda-1 pretreatment in ALDH2*2 mice with
3 months type-1 diabetes improved cardiac function as shown in LVP (E), +dP/dt (F), dP/dt (G) and as well as improved myocardial coronary perfusion pressure (H) after
ischemia-reperfusion injury (IRI) compared to Sham-operated controls. Data are
presented as mean ± SEM.
*p<0.05, **p<0.01, ***p<0.001

vs Sham Vehicle; #p<0.05,

##p<0.01, ###p<0.001

vs Sham
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Alda-1; $p<0.05, $$p<0.01 vs IRI Vehicle

Figure S9. Effect of Two-week Alda-1 pretreatment on ALDH2 activity and 4HNE
adducts in ALDH2*2 mice with 3 months of type-1 diabetes. ALDH2 activity data (A)
and Western blot images of 4HNE adducts and β-actin (B), and quantification data of
individual bands (C) in ALDH2*2 diabetic mice. Data are presented as mean ± SEM.
N=6 *p<0.05; ***p<0.001 vs Sham; #p<0.05; ###p<0.001 vs Vehicle

Figure S10. Effects of Alda-1 on malondialdehyde (MDA) adducts: Western blot
images of MDA adducts and β-actin from WT and ALDH2*2 mice with vehicle and
Alda-1 treatments (A) and the corresponding quantification data of MDA adducts (B)
were shown. Data are presented as mean ± SEM. *p<0.05 and **p<0.01.

Figure S11. Effects of Alda-1 on acrolein adducts: Western blot images of acrolein
adducts and β-actin from WT and ALDH2*2 mice with vehicle and Alda-1 treatments (A)
and the corresponding quantification data of acrolein adducts (B) were shown. Data are
presented as mean ± SEM. *p<0.05 and **p<0.01.
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